# Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

> **NCT00910728** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 65 (actual)

## Conditions studied

- Primary Myelofibrosis (PMF)
- Post-Polycythaemia Vera
- Essential Thrombocythaemia Myelofibrosis

## Interventions

- **DRUG:** AZD1480

## Key facts

- **NCT ID:** NCT00910728
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-03
- **Final completion:** 2014-08
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2017-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910728, "Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00910728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*